Some evidence suggests improvements in GLP1 response and a consecutive reduction of postprandial hyperglycemia, however, due to the paucity of evidence and the limited efficacy, we do not consider the use of DPP4-i as game changer in the treatment of T1D. The gene discussed is GLP1R; the disease is type 1 diabetes mellitus.